Therapeutic areas in which Haberman Associates principally works include:
Immune and inflammatory diseases
Central nervous system (CNS) diseases
Scroll down for a more in-depth look at some of our consulting engagements.
EXAMPLES OF CONSULTING ENGAGEMENTS WE HAVE PROVIDED
Provided strategic planning support and technology assessments for large and small biotechnology companies, major research products companies, and financial services companies. Technology and therapeutic areas included genomics, proteomics, other drug discovery technologies and applications, cancer, metabolic diseases, and infectious diseases.
Provided technology, scientific, and medical inputs as a key member of a team developing a technology and market-modeling database for a major pharmaceutical company, to guide resource allocation and new product strategy decisions in the area of diabetes and obesity drugs.
Assessed early-stage pipeline drug candidates in diabetes, obesity, and immune and inflammatory diseases for major pharmaceutical companies, in order to assist the companies in project selection and resource allocation decisions.
Produced a proprietary report on recent advances in the area of human adult and embryonic stem cells for the research products division of a major corporation, and made recommendations on developing potential commercial opportunities in the stem cell area. Further assessed opportunities for the same client in leading edge cell culture technologies that are applicable to stem cell and developmental biology R&D, drug discovery, in vitro ADME-Tox, and tissue engineering.
Identified and assessed opportunities in the life sciences for a major Japanese producer of plastics products, including microfluidics and protein arrays. Further assessed opportunities for the application of protein arrays to drug discovery and diagnostics, devised market-entry and partnering strategies, and identified potential North American and European partners. As a result of our efforts, the client entered into an R&D collaboration with a leading U.S. developer of protein arrays.